Trial · NCT04495283
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | APAP (Group B) | 0 | 35 | |
| other | COVID-19 | Infections and infestations | Placebo (Group C). | 0 | 17 | |
| other | Post procedural cellulitis | Infections and infestations | PGB and APAP (Group A) | 1 | 35 | |
| other | Post procedural cellulitis | Infections and infestations | APAP (Group B) | 0 | 35 | |
| other | Post procedural cellulitis | Infections and infestations | Placebo (Group C). | 0 | 17 | |
| other | Alanine aminotransferase increased | Investigations | PGB and APAP (Group A) | 1 | 35 | |
| other | Alanine aminotransferase increased | Investigations | APAP (Group B) | 0 | 35 | |
| other | Alanine aminotransferase increased | Investigations | Placebo (Group C). | 0 | 17 | |
| other | Aspartate aminotransferase increased | Investigations | PGB and APAP (Group A) | 1 | 35 | |
| other | Aspartate aminotransferase increased | Investigations | APAP (Group B) | 0 | 35 | |
| other | Aspartate aminotransferase increased | Investigations | Placebo (Group C). | 0 | 17 | |
| other | Transaminases abnormal | Investigations | PGB and APAP (Group A) | 1 | 35 | |
| other | Transaminases abnormal | Investigations | APAP (Group B) | 0 | 35 | |
| other | Transaminases abnormal | Investigations | Placebo (Group C). | 0 | 17 | |
| other | Transaminases increased | Investigations | PGB and APAP (Group A) | 2 | 35 | |
| other | Transaminases increased | Investigations | APAP (Group B) | 2 | 35 | |
| other | Transaminases increased | Investigations | Placebo (Group C). | 0 | 17 | |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | PGB and APAP (Group A) | 1 | 35 | |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | APAP (Group B) | 0 | 35 | |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Placebo (Group C). | 0 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04495283/events?page=3